Oxford, UK-based OMass Therapeutics closed on a $100 million Series B financing round. The round was led by new investors GV (formerly Google Ventures), Northpond Ventures and Sanofi Ventures. Three existing investors also participated: Syncona, Oxford Science Enterprise and Oxford University.
Nucleome Therapeutics appoints Dr Phil Boyd as Chief Financial Officer Phil brings more than 20 years of top-flight financial experience in the life sciences industry Oxford, UK